The effect of green coffee extract in the treatment of non-alcoholic fatty liver disease

Phase 2

Conditions: on-alcoholic fatty liver.
Fatty liver
K 76

Registration Number: IRCT201602113664N17

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 48

Inclusion Criteria

Nonalcoholic fatty liver (observation of liver steatosis on Sonographic image)
The age range of 20-50 years in women and 20-60 years in men
Body mass index greater than 25 and less than 35 kilograms per Square meters

Exclusion Criteria

Alcohol intake
Gestation, Lactation, and Menopause
Following a weight reducing diet
Professional athletes
History or current diagnosis of anemia, cardiovascular disease; gastrointestinal disease, diabetes, pulmonary disease, renal disease, acute or chronic liver disorders (Hepatitis A, B, ...), biliary impairments, biliary or kidney stones; autoimmune disease, cancers, Inherited disorders affecting the liver, and other diseases
Use of medications such as hepatotoxic drugs, anticoagulant drugs, hormonal drugs (e.g., oral contraceptives and/or estrogen), and consuming dietary supplements such as vitamin A, E, C, and omega-3 three months prior to the study and/or during the study period.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting Blood sugar. Timepoint: Baseline and after the intervention. Method of measurement: Spectrophotometery.;Liver Enzymes (Alanine aminotransferase, Aspartate aminotransferase). Timepoint: Baseline and after the intervention. Method of measurement: Spectrophotometery.;Serum leptin level. Timepoint: Baseline and after the intervention. Method of measurement: ELISA.;Liver Echogenicity. Timepoint: Baseline and after the intervention. Method of measurement: Liver sonography.;Body Mass Index. Timepoint: Baseline and after the intervention. Method of measurement: (weight/(Height)2),.;Insulin. Timepoint: Baseline and after the intervention. Method of measurement: ELISA.;Waist Circumference. Timepoint: Baseline and after the intervention. Method of measurement: Cm.;Serum adiponectin level. Timepoint: Baseline and after the intervention. Method of measurement: ELISA.;Oxidative status (TAC, MDA). Timepoint: Baseline and after the intervention. Method of measurement: Biochemical.

Secondary Outcome Measures